SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 528.65 |
| Enterprise Value ($M) | 533.78 |
| Book Value ($M) | 301.42 |
| Book Value / Share | 6.08 |
| Price / Book | 1.75 |
| NCAV ($M) | 95.70 |
| NCAV / Share | 1.93 |
| Price / NCAV | 5.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.53 |
| Return on Assets (ROA) | -0.38 |
| Return on Equity (ROE) | -0.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.05 |
| Current Ratio | 3.05 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 313.40 |
| Assets | 519.11 |
| Liabilities | 217.70 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Redmile Group, LLC | 9.90 | 31.42 | |
| 13G/A | Vanguard Group Inc | 8.83 | 0.00 | |
| 13G/A | Jpmorgan Chase & Co | 5.00 | -37.05 | |
| 13G/A | GIC Private Ltd | 2.37 | -52.60 | |
| 13G/A | State Street Corp | 5.98 | -3.13 | |
| 13G/A | BlackRock Inc. | 18.70 | 22.75 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 323,517 | 1,125,293 | 28.75 | |
| 118,093 | 478,732 | 24.67 | |
| 111,349 | 484,605 | 22.98 | |
| 95,362 | 620,473 | 15.37 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| REGN – Regeneron Pharmaceuticals, Inc. | REPL – Replimune Group, Inc. |
| RGEN – Repligen Corporation | RIGL – Rigel Pharmaceuticals, Inc. |
| RLMD – Relmada Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io